Lenz Therapeutics Announces U.S. Availability of VIZZ Eye Drops for Presbyopia

Product: Lenz Therapeutics, Inc. announced that VIZZ (aceclidine ophthalmic solution) 1.44%, the first FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, is now available. Top Line: VIZZ is powered by aceclidine, differentiated by its mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation. VIZZ contracts the iris sphincter muscle, resulting in a pinhole effect and uniquely achieves a sub-2 mm pupil that extends depth of focus to significantly improve near vision without causing a myopic shift. Close Up: “We are thrilled to introduce VIZZ to the 128 million adults living with blurry near vision in the United States,” said Eef Schimmelpennink, president and chief executive officer of Lenz Therapeutics. “Initial feedback and early brand awareness from the ECP community is extremely positive, and we feel well-positioned for a successful product launch, firmly establishing VIZZ as a Category of One for the treatment of presbyopia.” Vital Statistics: Commercial product shipments of VIZZ were initiated to consumers in October through the company’s ePharmacy partner and are anticipated to be broadly available, including via retail pharmacies, by mid-Q4 2025. https://lenz-tx.com/